DGAP-News: CO.DON AG: Subscription period for convertible bonds and bonds with warrants successfully completed

Subscription period for convertible bonds and bonds with warrants successfully completed

Berlin / Teltow, 7 June 2018 - The subscription period for the convertible bonds with a total nominal amount of up to EUR 15.3 million and bonds with warrants with a total nominal amount of up to EUR 2.0 million ended yesterday. On 23 May 2018 the Executive Board of CO.DON AG decided with the approval of the Supervisory Board to issue non-interest bearing convertible bonds and bonds with warrants with maturities of three years.

The convertible bonds are divided into up to 153 partial bonds, each with a nominal amount of EUR 100,000, and an issue price of EUR 80,000. The bonds with warrants are divided into a maximum of 20 partial bonds of EUR 100,000 each. Both bonds were offered for subscription to the shareholders of the CO.DON AG. If bonds should remained unsold, a foreign financial investor has committed to acquiring them, on condition that the financial investor can purchase at least 70% of both the convertible bonds and the bonds with warrants.

Until the end of the subscription period of the convertible bonds and bonds with warrants, 28,1% of the convertible bonds and 25% of the bonds with warrants have been subscribed for by the shareholders, whereby 26.8% of the convertible bonds and 25% of the bonds with warrants have been subscribed for by the major shareholder of CO.DON AG, Bauerfeind Beteiligungsgesellschaft mbH. At the same time this satisfies the condition for the investor to acquire the remaining 71,9% of the convertible bonds and 75 % of the bonds with warrants tomorrow, 8 June 2018.

Ralf Jakobs, CEO of CO.DON AG: "Firstly I would like to thank Prof. Bauerfeind for his commitment and his willingness to express his confidence in the company in such an important funding operation by subscribing for the bonds. The confidence shown by both Prof. Bauerfeind and the investor, a strategic US financial group with great experience in healthcare and biotech, and with global operations, are both an incentive and a spur for us to fulfil the expectations placed in me and all of us to implement the business case, but also to deliver the company's future strategic international expansion and consistent portfolio strategy and to continue resolutely on the course set as part of our strategic planning.

The funding means that CO.DON AG is now financed through to break-even on current strategic plans. At the same time it opens up the possibility of further internationalisation beyond Europe. We will continue to expand our product portfolio in order to keep fulfilling our role as "Human Cell Experts" in the years ahead and to offer innovative products for a growing and important market."

CO.DON AG develops, produces and markets autologous cell therapies for the minimally-invasive repair of cartilage damage in the knee joint following traumatic or degenerative defects. Spherox is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). The treatment has been used in over 200 clinics to treat more than 12,000 patients. The company received EU marketing authorisation for Spherox in July 2017. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.
Further information is available from www.codon.de

Investor Relations and Press Contact:
Matthias Meißner, M.A.
Director Investor Relations / Public Relations
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309
Email: ir@codon.de